OS-031 Imdusiran (AB-729) Administered Every 8 Weeks for 24 Weeks Followed by the Immunotherapeutic VTP-300 Maintains Lower HBV Surface Antigen Levels in NA-suppressed CHB Subjects Than 24 Weeks of Imdusiran Alone

Kosh Agarwal,Man-Fung Yuen, Stuart Roberts, Gin-Ho Lo,Chao-Wei Hsu,Wan-Long Chuang,Chi-Yi Chen,Pei-Yuan Su, Sam Galhenage,Sheng-Shun Yang,Emily P. Thi,Katie Anderson,Deana Antoniello,Elina Medvedeva,Timothy Eley, Tilly Varughese,Louise Bussey,Charlotte Davis, Antonella Vardeu, Christine L. Espiritu,Sharie C Ganchua,Christina Iott, Elizabeth Eill, Tom Evans, Karen D Sims

Journal of Hepatology（2024）

引用 0|浏览0

暂无评分

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要